Acute coronary syndrome
Item
Participants hospitalized with acute coronary syndrome (ACS)
boolean
C0948089 (UMLS CUI-1)
PCI
Item
anticipated to undergo percutaneous coronary intervention (PCI)
boolean
C1532338 (UMLS CUI-1)
Informed consent
Item
Participants provide signed informed consent form (ICF)
boolean
C0021430 (UMLS CUI-1)
Weight
Item
Participants weigh at least 60 kilograms (kg) at the time of screening
boolean
C0005910 (UMLS CUI-1)
Pregnancy
Item
test negative for pregnancy at the time of enrollment based on a urine or serum pregnancy test
boolean
C0549206 (UMLS CUI-1)
Cardiogenic shock
Item
Have cardiogenic shock at the time of randomization
boolean
C0036980 (UMLS CUI-1)
Ventricular arrhythmia
Item
Have refractory ventricular arrhythmias
boolean
C0085612 (UMLS CUI-1)
Congestive heart failure
Item
Have New York Heart Association (NYHA) Class IV congestive heart failure
boolean
C0018802 (UMLS CUI-1)
Systolic blood pressure
Item
Have systolic blood pressure greater than 180 mm Hg, or diastolic blood pressure greater than 100 mm Hg on more than 1 assessment at any time from participant presentation of ACS treatment to enrollment
boolean
C0871470 (UMLS CUI-1)
Diastolic blood pressure
Item
Have systolic blood pressure greater than 180 mm Hg, or diastolic blood pressure greater than 100 mm Hg on more than 1 assessment at any time from participant presentation of ACS treatment to enrollment
boolean
C0428883 (UMLS CUI-1)
Thrombolytic therapy
Item
Have received fibrin-specific fibrinolytic therapy less than 24 hours prior to randomization
boolean
C0040044 (UMLS CUI-1)
Hemorrhage
Item
Have active internal bleeding or history of bleeding diathesis
boolean
C0019080 (UMLS CUI-1)
Bleeding risk
Item
Have clinical findings associated with an increased risk of bleeding
boolean
C3251812 (UMLS CUI-1)
History of stroke
Item
Prior history of ischemic or hemorrhagic stroke
boolean
C0559159 (UMLS CUI-1)
Intracranial neoplasm
Item
Intracranial neoplasm
boolean
C1527390 (UMLS CUI-1)
arteriovenous malformation
Item
arteriovenous malformation
boolean
C0003857 (UMLS CUI-1)
aneurysm
Item
aneurysm
boolean
C0002940 (UMLS CUI-1)
History of TIA
Item
Prior history of transient ischemic attack (TIA)
boolean
C0455536 (UMLS CUI-1)
INR
Item
Have an International Normalized Ratio (INR) known to be greater than 1.5 at the time of evaluation
boolean
C0525032 (UMLS CUI-1)
Platelet count
Item
Have a platelet count of less than 100,000 per cubic millimeter (mm^3) at the time of evaluation
boolean
C0032181 (UMLS CUI-1)
Anemia
Item
Have anemia [hemoglobin (Hgb) less than 10 grams per deciliter (g/dL)] at the time of evaluation
boolean
C0002871 (UMLS CUI-1)
Thienopyridines
Item
Have received 1 or more doses of a thienopyridine or other adenosine diphosphate (ADP) receptor inhibitor within 10 days prior to screening
boolean
C2936588 (UMLS CUI-1)
GPIIb/IIIa antagonist
Item
Have been administered glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor within the past 7 days or planned use of a GPIIb/IIIa inhibitor during PCI
boolean
C3640054 (UMLS CUI-1)
Oral anticoagulants
Item
Are receiving or will receive oral anticoagulation or other antiplatelet therapy, other than aspirin (ASA), which cannot be safely discontinued for the duration of the study.
boolean
C0354604 (UMLS CUI-1)
NSAID
Item
Are receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued during the study
boolean
C0003211 (UMLS CUI-1)
Pregnancy
Item
Are women who are known to be pregnant
boolean
C0549206 (UMLS CUI-1)
Breastfeeding
Item
Breastfeeding
boolean
C0006147 (UMLS CUI-1)
Liver failure
Item
Have known severe hepatic dysfunction (that is, with cirrhosis or portal hypertension)
boolean
C0085605 (UMLS CUI-1)
Aspirin allergy
Item
Have a history of intolerance or allergy to aspirin or approved thienopyridines (ticlopidine, clopidogrel or prasugrel)
boolean
C0004058 (UMLS CUI-1)
